Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia
Sponsor: Riphah International University
Summary
The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are: * To determine the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea) on hemoglobin level and blood transfusion in beta thalassemia patients. * To determine the safety of HbF inducers (combination therapy: thalidomide and hydroxyurea) in beta thalassemia patients * To determine effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on quality of life of beta thalassemia patients
Official title: Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia: a Prospective 12 Months Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2026-06-20
Completion Date
2027-06-19
Last Updated
2026-06-29
Healthy Volunteers
No
Conditions
Interventions
Thalidomide
Tab Thalidomide 0.5 to 4 mg/kg orally every day for 12 months
Hydroxy Urea
Tab Hydroxyurea 10-20 mg/kg per day for 12 months
Locations (1)
Riphah International University
Rawalpindi, Punjab Province, Pakistan